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Abstract Either oxaliplatin- or irinotecan-containing
regimen could receive a good effectiveness in patients with
metastatic colorectal cancer as the first-line chemotherapy,
but not all patients would benefit from the treatment they
have received. This study was to investigate the role of
single nucleotide polymorphisms (SNPs) of methylenete-
trahydrofolate reductase (MTHFR) and ATP-binding cas-
sette sub-family G member 2 (ABCG2) in selecting the
most appropriate treatment for individual patients. Ninety-
two metastatic colorectal cancer patients treated with first-
line 5-fluoropyrimidine (5-FU), leucovorin, and oxaliplatin
(FOLFOX), capecitabine, and oxaliplatin (XELOX) and
sixty-two patients receiving 5-FU, leucovorin, and irino-
tecan (FOLFIRI) were reviewed. The SNPs of MTHFR and
ABCG2 were detected using gene sequencing method after
DNA PCR amplification, which was extracted from
peripheral blood karyocytes. Clinical characteristics and
gene polymorphisms were evaluated in univariate and
multivariate analysis as predictive factors for response rate
(RR) and progression-free survival (PFS). In patients
bearing 2–4 genotypes of MTHFR 677C/C, MTHFR 1298
A/C or C/C, ABCG2 34G/G, and ABCG2 421C/A or A/A,
those who received oxaliplatin-based chemotherapy
achieved a higher RR (41.7 vs. 18.8 %, P = 0.027) and
longer median PFS (mPFS) than irinotecan-based therapy
[8.9 vs. 7.1 m, FOLFIRI: hazard ratio (HR) = 1.722, 95 %
confidence interval (CI) 1.026–2.892, P = 0.040, com-
pared with FOLFOX/XELOX]; on the contrary, patients
carrying 0 or 1 above genotype exhibited better outcomes
after receiving FOLFIRI chemotherapy (mPFS: 9.3 vs.
6.4 m, FOLFIRI: HR = 0.422, 95 % CI 0.205–0.870,
P = 0.019, compared with FOLFOX/XELOX). Combina-
tion of SNPs with MTHFR and ABCG2 may play a role in
helping clinicians to select first-line chemotherapy for
patients with metastatic colorectal cancer.
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Introduction
Colorectal cancer (CRC) is one of the commonly diag-
nosed cancers among patients, which ranks the third for
males and the second for females worldwide. For the
fatality rate, it ranks the fourth and the third for males and
females, respectively [1].
Systemic combination chemotherapy is the mainstay of
the treatment for patients with metastatic colorectal cancer
(mCRC). Treatment for patients with mCRC has evolved
significantly over the last 10 years with the use of new
active cytotoxic agents, including oxaliplatin and irino-
tecan plus targeted monoclonal antibodies bevacizumab,
cetuximab, and panitumumab; 5-fluoropyrimidine (5-FU),
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leucovorin (CF), and oxaliplatin (FOLFOX), capecitabine,
and oxaliplatin (XELOX) or 5-FU, CF, and irinotecan
(FOLFIRI) are the standard chemotherapy treatment for
metastatic colorectal cancer in practice with equivalent
treatment effectiveness [2–4]. However, some patients do
not necessarily benefit from the treatment they have
received, but are exposed to the adverse effects nonetheless
[5]. Therefore, it is of great importance to identify bio-
markers that could help select the optimum regimen for
each patient.
Genetic polymorphisms in drug target genes, genes
encoding DNA repair enzymes, and detoxification pathways
may influence the activity of the drug. Single nucleotide
polymorphism (SNP) refers to the DNA sequence poly-
morphisms caused by single nucleotide variations occurred
at the genomic level with the probability greater than 1 %,
which sometimes can affect the expression or activity of its
encoded protein and therefore affects its function. With
respect to the cancer treatment, SNP would be related to
different therapeutic efficacy and adverse reactions.
As the common drug in FOLFOX, XELOX, and FOLFIRI
regimens, 5-FU or its derivate remains the basis for colorectal
cancer chemotherapy. Optimal cytotoxicity of fluoropyrimi-
dines requires elevated 5, 10-methylenetetrahydrofolate
(CH2FH4) tumoral concentrations, controlled by the methy-
lenetetrahydrofolate reductase (MTHFR) enzyme, which
irreversibly converts CH2FH4 into 5-methyltetrahydrofolate.
The MTHFR gene is subject to several polymorphisms, of
which the 677C[T and 1298A[C SNPs are the two most
commonly linked with altered enzyme activity. Accordingly,
experimental data have shown that rare MTHFR variants in
position 677 and 1298 are more sensitive to 5-FU [6–9].
However, results of clinical data do not concord regarding the
influence of MTHFR genotype on 5-FU responsiveness or
patients’ survival [10–12].
Breast cancer resistance protein (BCRP/ABCG2) is an
ATP-binding cassette transporter, which may directly
cause resistance of cancer cells by active efflux of anti-
cancer drugs. It has been found that there are more than 40
SNPs in ABCG2 gene, the most common two of which are
the 421C[A in exon 5 and 34G[A in exon 2. Numerous
in vitro studies have shown that 421A cells have a reduced
resistance to irinotecan and its active product SN-38 [13,
14], while the polymorphisms of 421C[A in ABCG2 gene
has no effect on the pharmacokinetics of hydrochloric acid
irinotecan based on the blood sample from 84 European
patients [15]. As for ABCG2 34G[A, Mcleod [16] reported
at the 2008 ASCO annual meeting that this polymorphism
was associated with relative susceptibility to FOLFOX and
resistance to FOLFIRI (P \ 0.013, Caucasians only). The
research results remind us that the respective benefit pop-
ulations of different chemotherapy regimens could be dis-
tinguished through the study of single nucleotide
polymorphisms. If this conclusion could be confirmed by
more researches, this SNP may provide evidence for
selecting FOLFOX or FOLFIRI therapy for patients with
advanced colorectal patients.
In the present study, we detected the SNPs in MTHFR
677C[T, 1298A[C, ABCG2 34G[A, and 421C[A in
patients with mCRC who had received FOLFOX/XELOX
or FOLFIRI as first-line chemotherapy, and combined with
the clinical features, we investigated the potential markers
for selecting the first-line chemotherapy.
Methods
Patients
We retrospectively collected the data for advanced colo-
rectal cancer patients who received first-line standard
FOLFOX, XELOX, or FOLFIRI regimen between January
2009 and May 2011 at Fudan University Shanghai Cancer
Center. Subjects eligible for this study must meet the fol-
lowing criteria: (1) pathologically confirmed colorectal
adenocarcinoma with unrespectable and appraisable metas-
tasis or relapse; (2) must have received first-line FOLFOX,
XELOX, or FOLFIRI chemotherapy for at least 2 cycles; (3)
age between 18 and 75; (4) ECOG 0-1; and (5) peripheral
blood sample was reserved in our tissue bank. Written
informed consent was obtained from all patients as well.
Genotyping
Genomic DNA was isolated from whole blood using the
FUJIFILM DNA extraction kit. Based on previous published
studies, the single nucleotide polymorphisms selected for
testing were MTHFR 677C[T (rs1801133, Ala 222 Val) and
1298A[C (rs1801131, Glu 428 Ala), and ABCG2 34G[A
(rs2231137, Val 12 Met) and 421C[A (rs2231142, Gln 141
Lys). Genotyping for the SNPs was determined using py-
rosequencing. Primers used were F, 50-GGAAGGTGCAAG
ATCAGAGC-30 and R, 50-CTGGGAAGAACTCAGCGAA
C-30 for amplification of codon 222 of MTHFR; F, 50-CCAG
ACCAAAGAGTTACATCTACCG-3 and R, 50-CTTACCC
TTCTCCCTTTGCCA-30 for codon 428 of MTHFR; F, 50-T
TCCAAGTTGTGCCTGTC-30 and R, 50-AAGCCATTGGT
GTTTCC-30 for codon 12 of ABCG2; and F, 50-GGATGAT
GTTGTGATGGGCACTCT-30 and R, 50-GGAAAGCAAC
CATTTTTGACCATAC-30 for codon 141 of ABCG2.
Statistics
According to RECIST (version 1.1), the response to
treatment was assessed by clinical and radiologic exami-
nation using CT scan or MRI of the chest, abdomen, and
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pelvis. Objective response rate (RR) refers to the percent-
age of patients having complete response (CR) or partial
response (PR). Patients with stable disease (SD) or pro-
gressive disease (PD) are defined as nonresponders. Pro-
gression-free survival (PFS) is defined as the time interval
from the start of first-line chemotherapy to first disease
progression or death from any cause if disease progression
does not occur. Alive patients without progression will be
censored at the last follow-up.
PFS was estimated by the Kaplan–Meier method. The
relationship between prognostic factors and PFS was
explored using log-rank test and Cox regression model for
univariate and multivariate analyses, respectively. Pear-
son’s v2 test or Fisher’s exact test was used to assess the
association between predictive factors and RR, while for
multivariate analyses, binary logistic regression model was
employed. P values were two-tailed for all the tests, and
statistical significance was set as P \ 0.05. Analyses were
conducted using SPSS 17.0.
Results
Patient characteristics
Of all 154 patients enrolled, ninety (58 %) patients were
male, and 64 (42 %) were female, with a median age of 56
(range 30–75). All treated patients had an ECOG PS of 0 or
1. Ninety-two patients were diagnosed with rectal cancer
and 62 with colon cancer. Radical resection of the primary
tumor had been performed in 86 % of the patients
(n = 132). Synchronous metastasis occurred in 78 patients,
and metachronous metastasis or relapse occurred in 76
patients. Ninety-five patients had a single metastatic organ,
and 59 had more than one metastatic organs. One patient
achieved CR (1 %), 48 patients achieved PR (31 %), 75
patients had SD (49 %), and 29 had PD (19 %), with a RR
of 32 %. Until March 12, 2012, one hundred and thirty-
seven (89 %) patients have progressed, with the mPFS of
8.1 months [95 % confidence interval (CI) 6.9–9.3].
Among them, 92 patients received oxaliplatin-containing
regimen (FOLFOX or XELOX), with a RR of 35.9 % and
mPFS of 8.3 months; the rest 62 patients were treated with
FOLFIRI chemotherapy, with a RR of 26.2 % and mPFS of
8.1 months. No significant differences were observed for
either RR (P = 0.211) or PFS (P = 0.443) between the
two regimens. Table 1 presents the demographic charac-
teristics of the participants enrolled in the study. There was
no significant difference in age, gender, primary site of
tumor, radical resection of primary tumor, and the number
of metastatic organs, between two groups of patients
treated with different regimens, except the time of metas-
tasis. Of all 154 patients, each of the genotypes of MTHFR
1298A[C and ABCG2 34G[A was not available for one
patient, respectively. Table 2 illustrates the distributions of
genotypes for the SNPs.








Mean ± SD 56.07 ± 9.6 54.98 ± 9.8 0.826
Gender
Male 56 (60.9) 34 (54.8) 0.456
Female 36 (39.1) 28 (45.2)
Primary site
Rectum 54 (58.7) 38 (61.3) 0.747
Colon 38 (41.3) 24 (38.7)
Radical resection of primary
site
Yes 78 (84.8) 54 (87.1) 0.687
No 14 (15.2) 8 (12.9)
Number of metastatic organs
Single 59 (64.1) 36 (58.1) 0.448
Multiple 33 (35.9) 26 (41.9)
Time of metastasis
Heterochrony 29 (31.5) 47 (75.8) 0.000
Synchrony 63 (68.5) 15 (24.2)
Bold value indicates statistical significance
FOLFOX 5-fluoropyrimidine, leucovorin, and oxaliplatin, XELOX
capecitabine and oxaliplatin, FOLFIRI 5-fluoropyrimidine, leucovo-
rin, and irinotecan, SD standard deviation
Table 2 The genotypes distributions of MTHFR and ABCG2 genes

















MTHFR methylenetetrahydrofolate reductase, ABCG2 ATP-binding
cassette sub-family G member 2
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Predictive factors
For patients receiving FOLFOX/XELOX chemotherapy, RR
was higher and PFS was longer in patients carrying MTHFR
677C/C, 1298 A/C or C/C, ABCG2 34G/G, or 421C/A or
A/A; in contrast, for patients treated with FOLFIRI, RR was
lower and PFS was shorter in those genotypes, except that
there was no difference in PFS between patients bearing
MTHFR 677C/C and a genotype containing T. However,
there were almost no significant differences, except ABCG2
421C[A in RR for patients treated with FOLFOX/XELOX
(seen in Table 3). Based on these results, we defined MTHFR
677C/C, MTHFR 1298 A/C or C/C, ABCG2 34G/G, and
ABCG2 421 C/A or A/A as the favorable genotypes for
FOLFOX/XELOX regimen, and each was defined as 1 point
each, while the opposite genotype was 0 point each. A score
of 0–4 was calculated for each patient. Two groups were
identified according to the score: a low-score group (0–1
point), and high-score group (2–4 points). The univariate
analysis showed that in the low-score group, patients treated
with FOLFIRI had a longer mPFS than those administrated
by FOLFOX/XELOX (9.3 vs. 6.4 months, P = 0.604,
Fig. 1), and PFS was significantly associated with radical
resection of primary lesion, the number of metastatic organs,
and the time of metastasis, while in the high-score group,
patients receiving FOLFIRI had a shorter mPFS than those
treated with FOLFOX/XELOX (7.1 vs. 8.9 months,
P = 0.192, Fig. 2), and PFS was significantly associated
with radical resection of primary lesion. These three vari-
ables were introduced in the multivariate analysis, along
with the first-line chemotherapy. After being adjusted for
radical resection of primary lesion, the number of metastatic
organs, and the time of metastasis, patients treated with
FOLFIRI were associated with a 57.8 % reduced risk of
disease progression [adjusted hazard ratio (HR) = 0.422,
95 % CI 0.205–0.870, P = 0.019] compared with FOLFOX/
XELOX, while in the high-score group, patients receiving
FOLFIRI were associated with a 72.2 % increased risk of
disease progression (adjusted HR = 1.722, 95 % CI
1.026–2.892, P = 0.040) (seen in Tables 4 and 5). As for
RR, the univariate analysis showed in the low-score group,
patients treated with FOLFIRI had a higher RR than those
treated with FOLFOX/XELOX (55.8 vs. 44.4, P = 0.417),
while in the high-score group, the RR was significantly
higher in patients treated with FOLFOX/XELOX (41.7 vs.
18.8, P = 0.027). However, the multivariate analysis
showed no significant differences.
Discussion
While the fatality rate for colorectal cancer has been
decreasing in several developed countries, the rate con-
tinues to increase in many developing countries with lim-
ited resources and health infrastructure [1]. Even with the
application of the new drugs of oxaliplatin and irinotecan,
Table 3 The relationship














cassette sub-family G member 2
Genotype RR (%) FOLFOX/XELOX group FOLFIRI group P value
P value mPFS (m) P value RR (%) P value mPFS (m)
MTHFR-677
C/C 43.6 0.185 10.0 0.434 18.8 0.428 8.1 0.178
C/T ? T/T 30.2 7.0 28.3 8.1
MTHFR-1298
A/A 34.5 0.857 7.6 0.763 30.2 0.231 8.7 0.199
A/C ? C/C 36.4 0.108 8.4 0.472 15.8 0.357 7.2 0.220
ABCG2-34
G/G 44.4 8.9 19.2 6.3
G/A ? A/A 28.3 6.7 30.6 9.3
ABCG2-421
C/C 21.6 0.019 6.6 0.212 30.4 0.561 9.1 0.757
C/A ? A/A 45.5 8.9 23.1 7.5
Fig. 1 Kaplan–Meier estimation of PFS by the first-line chemother-
apy in low-score group
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still nearly half of the advanced colorectal patients could
not benefit from the chemotherapy they received. Even
though FOLFOX, XELOX, and FOLFIRI have similar
efficacy on either RR, PFS, or OS, until recently, little is
known about how to select the first-line chemotherapy for
patients with metastatic colorectal cancer.
We identified two groups suitable for different regimens
depending on the SNPs of MTHFR and ABCG2. Patients
carrying 0–1 of MTHFR 677C/C, MTHFR 1298A/C or
C/C, ABCG2 34G/G, and ABCG2 421C/A or A/A geno-
types had higher RR and longer PFS when treated with
FOLFIRI regimen as the first-line chemotherapy, while
patients carrying 2–4 of above genotypes had higher RR
and longer PFS after treated with FOLFOX or XELOX. To
our knowledge, this is the first study to explore the pre-
dictive biomarkers to select the first-line regimen for
patients with mCRC published to date.
In this study, we analyzed the data for 154 patients with
advanced colorectal cancer who had received FOLFOX,
XELOX, or FOLFIRI as the first-line chemotherapy. In the
FOLFOX/XELOX group, the RR was 36 %, and the PFS
was 8.3 months, while in the FOLFIRI group, the RR and
PFS were 26.2 % and 8.1 months, respectively. No signif-
icant differences were observed between the two groups,
which was similar with the results reported previously.
There have been no predictive biomarkers for choosing the
first-line chemotherapy for patients. In our study, we
investigated the predictive role of SNPs of MTHFR and
ABCG2 for selecting the first-line treatment. MTHFR irre-
versibly converts CH2FH4 into CH3FH4, and intracellular
CH2FH4 concentration is mainly controlled by MTHFR
[17]. In agreement, experimental [18] and clinical [19]
studies have established that optimal 5-FU cytotoxicity
requires elevated CH2FH4 tumoral concentrations. A study
by Cohen et al. [7] is the first that reported a link between the
MTHFR genotype and tumor response to 5-FU-based che-
motherapy, among which of 43 metastatic colorectal cancer
patients receiving exclusive 5-FU therapy, all five 677TT
patients responded to the treatment, whereas the response
rate was approximately 50 % in 677CC patients. Terrazzino
et al. [8] found that in rectal cancer patients receiving 5-FU-
based chemotherapy and radiotherapy, patients not carrying
the MTHFR 677T-1298A haplotype exhibited a higher
response rate than patients with the MTHFR 677T-1298A
haplotype (P = 0.002). By contrast, most studies containing
advanced colorectal cancer patients receiving 5-FU associ-
ated with irinotecan or oxaliplatin failed to show a link
between the two MTHFR polymorphisms (677C[T and
1298A[C) and RR or survival [11, 20, 21]. Thus, some
researchers considered that the predictive role of MTHFR
polymorphisms on 5-FU responsiveness has been reported
in studies where 5-FU was the central drug; however, it
would appear that the presence of oxaliplatin or irinotecan in
current 5-FU-based treatment could blur the influence of
MTHFR polymorphisms on the treatment outcomes [22].
Exact mechanism remains unclear, which is needed eluci-
dating by further studies.
ABCG2 is a member of the ABC transporter family,
which was first cloned from doxorubicin-resistant human
MCF-7 breast cancer cells and was named breast cancer
resistance protein (BCRP) [23]. ABCG2 is a transmem-
brane transporter that carries out many chemotherapy drugs
out of cells, including CPT-11 and its active metabolite
SN-38 [24]. The SNPs of ABCG2 affect the pharmacoki-
netics of many drugs by affecting either expression of
ABCG2, the activity of ABCG2, or the transport efficiency
of substrate. The data presented by Kobayashi suggested
Fig. 2 Kaplan–Meier estimation of PFS by the first-line chemother-
apy in high-score group
Table 4 The multivariate analysis of PFS in low-score group
Variable HR 95 % CI P value
First-line FOLFIRI 0.422 0.205–0.870 0.019
Synchronous metastasis 0.238 0.094–0.600 0.002
Radical resection of primary site 0.171 0.061–0.480 0.001
Multiple metastatic organs 0.823 0.435–1.554 0.548
Bold values indicate statistical significance
PFS progression-free survival, HR hazard ratio, CI confidence inter-
val, FOLFIRI 5-fluoropyrimidine, leucovorin, and irinotecan
Table 5 The multivariate analysis of PFS in high-score group
Variable HR 95 % CI P value
First-line FOLFIRI 1.722 1.026–2.892 0.040
Synchronous metastasis 1.757 1.028–3.003 0.039
Radical resection of primary site 0.726 0.345–1.527 0.399
Multiple metastatic organs 1.424 0.836–2.426 0.194
Bold values indicate statistical significance
PFS progression-free survival, HR hazard ratio, CI confidence inter-
val, FOLFIRI 5-fluoropyrimidine, leucovorin, and irinotecan
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that the 421C[A variant in the BCRP gene, a common
SNP in both Japanese and Caucasian populations, alters
protein levels and lowers the activity of its ATP enzyme,
thus increasing the sensitivity of anticancer drugs. Vitro
studies indicated that 421A-cells have a lower drug resis-
tance to CPT-11 and SN-38 [13, 14]. The report presented
at 2008 ASCO annual meeting, which indicated that
ABCG2 34G[A was associated with relative susceptibility
to FOLFOX and resistance to FOLFIRI [16], aroused us to
analyze the predictive value of SNP for different chemo-
therapy regimens.
Our study found that single SNP has no predictive role
on efficacy or survival for the patients treated with FOL-
FOX/XELOX or FOLFIRI. However, when several SNPs
combined, favorable patients for different regimens can be
separated: Patients carrying 2–4 of MTHFR 677C/C,
MTHFR 1298 A/C or C/C, ABCG2 34G/G, and ABCG2
421C/C or A/A may benefit more from FOLFOX/XELOX
regimen as the first-line chemotherapy. On the other side,
patients carrying 0–1 above genotype may get more ben-
efits from the chemotherapy of FOLFIRI.
Conclusively, the results of the study indicated that the
combination of SNPs may play a role in determining the
first-line chemotherapy for patients. However, the limita-
tions of the retrospective study, mainly small sample size,
could affect final results. Therefore, these results need to be
validated in a larger prospective study further to seek the
predictive scale to determine the best treatment for
patients, combined with other biomarkers, such as micr-
oRNA, mRNA, or protein. To elucidate the mechanism
underlying the polymorphisms and chemotherapy efficacy,
further functional evaluations are needed.
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